---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-279778"
form_type: "8-K"
ticker: "FBLG"
cik: "0001958777"
company_name: "FibroBiologics, Inc."
filed_at: "2026-06-23T21:16:01+00:00"
generated_at: "2026-06-23T21:18:31.865043+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# FibroBiologics annual meeting approves 2026 equity plan, re-elects director

## Summary
- Stockholders approved the 2026 Equity and Incentive Plan with 2.62M for, 297k against; 2.06M shares available, including 2M new shares and 61,968 from prior plan.
- Pete O'Heeron re-elected as Class III director with 2.80M for, 119k against; Stacy Coen did not stand for re-election.
- Ratified WithumSmith+Brown as auditor for FY 2026 with 4.11M for, 43k against.
- Approved issuance of up to 2.27M shares from March SPA warrants and 159k shares from H.C. Wainwright engagement letter.
- 4.17M shares represented out of 6.83M eligible; all four proposals passed.

## SEC filing metadata
- accession: 0001193125-26-279778
- form_type: 8-K
- ticker: FBLG
- cik: 0001958777
- company_name: FibroBiologics, Inc.
- filed_at: 2026-06-23T21:16:01+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1958777/000119312526279778/0001193125-26-279778-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1958777/000119312526279778/fblg-20260622.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-279778
- JSON: https://secwatch.observer/filing/0001193125-26-279778.json
- Plain text: https://secwatch.observer/filing/0001193125-26-279778.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.